Log in to save to my catalogue

SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Mus...

SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Mus...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7659233

SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group

About this item

Full title

SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group

Publisher

England: John Wiley and Sons Inc

Journal title

Cancer science, 2012-09, Vol.103 (9), p.1625-1630

Language

English

Formats

Publication information

Publisher

England: John Wiley and Sons Inc

More information

Scope and Contents

Contents

In the present study, we evaluated the safety and effectiveness of SYT‐SSX‐derived peptide vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT‐SSX fusion region (B peptide) and its HLA‐A*2402 anchor substitute (K9I) were synthesized. In Protocols A1 and A2, vaccines with peptide alone were administered subcutaneous...

Alternative Titles

Full title

SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7659233

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7659233

Other Identifiers

ISSN

1347-9032

E-ISSN

1349-7006

DOI

10.1111/j.1349-7006.2012.02370.x

How to access this item